Examining the Role of BTK Inhibitors in Mantle Cell Lymphoma

The choice of BTK inhibitor regimen for patients with chronic lymphocytic leukemia must be tailored to the patient, taking into consideration their preferences and comorbidities, as well as potential treatment-related adverse effects.

Related Keywords

Fondazione Italiana Linfomi , European Mantle Cell Lymphoma Network , Mantle Cell Lymphoma International Prognostic Index , European Mantle Cell Lymphoma , Fondazione Italiana , Clin Cancer , Ibrutinib , Zanubrutinib , Sequoia Trial , Winthropp Rockefeller Cancer Institute At The University Of Arkansas For Medical Sciences , Uams College Of Medicine , Mantle Cell Lymphoma , Nhl , Ct01776840 , Ct02972840 , Ct03112174 , Shine Trial , Ace Ly 308 Trial , Sympatico Trial , Venetoclax , Bendamustine Rituximab , Acalabrutinib , Aim Trial , Ct02471391 , Phase 2 Zuma Study Nct02601313 ,